Guidance
Our Guidance explains the laws and regulations governing the development, manufacturing, marketing, and supply of therapeutic goods in Australia.
We recently introduced new features to improve your experience using Guidance on our website.
Use the filters below to narrow your search.
Filter results
You can narrow down the results using the filters.
Product type
Topic
- Advertising (32)
- Breast implant hub (1)
- Clinical trials (5)
- Committees and advisory bodies (2)
- Compliance and enforcement (30)
- Cosmetics (4)
- COVID-19 (11)
- Fees and payments (3)
- Import and export (9)
- Labelling and packaging (26)
- Legislation (9)
- Manufacturing (41)
- Medicinal cannabis hub (4)
- Metal-on-metal hip replacement implants hub (1)
- Safety monitoring and information (46)
- Scheduling (national classification system) (6)
- Shortages and supply disruptions (3)
- Sunscreens (2)
- Unique Device Identification (UDI) hub (2)
- Vaping hub (5)
- Weight loss products (1)
Search
24 result(s) found, displaying 1 to 24
-
GuidanceProvides guidance on the regulatory requirements for labels and other medicine presentation.
-
GuidanceGuidance on providing adventitious agent safety information in applications for medicines containing, or manufactured using, materials of animal or human origin.
-
GuidanceGuidance for data requirements for microorganisms used as active ingredients in listed or registered complementary medicines. These are generally referred to as probiotics or postbiotics.
-
GuidanceGuidance on TGO 109: Standards for Biologicals - General and Specific Requirements.
-
GuidanceGuidance for industry organisations applying to add a medicine to the Australian Register of Therapeutic Goods (ARTG).
-
GuidanceAn overview of the Data Protection Scheme for assessed listed medicines, and the criteria that must be met for information to be considered protected under the Scheme.
-
GuidanceThis guidance will help you understand our pharmacovigilance inspection program (PVIP).
-
GuidanceGuidance explaining how the method of preparation influences classification and whether autologous HCTs are eligible for exemptions.
-
GuidanceGuidance for sponsors or suppliers of biologicals in Australia on their ongoing responsibilities after a product is included on the Australian Register. of Therapeutic Goods (ARTG).
-
GuidanceGuidance for sponsors of faecal microbiota transplant (FMT) products, which are regulated as biologicals.
-
GuidanceGuidance to help determine whether products are separate and distinct biologicals that will need to be included as separate ARTG entries.
-
GuidanceGuidance on TGO 107: Mandatory labelling requirements for biologicals and human cell and tissue materials.
-
GuidanceGuidance to help work out if your autologous HCT product is exempt from some aspects of our regulation.
-
GuidanceGuidance on changing information in the ARTG for listed or assessed listed medicines.
-
GuidanceThis guidance describes the requirements for manufacturers and sponsors of faecal microbial transplant (FMT) products in TGO 105.
-
GuidanceAustralian Regulatory Guidelines for Biologicals (ARGB). This guidance will help you understand how to classify your biological.
-
Applying for a Class 1 biological to be added in the Australian Register of Therapeutic Goods (ARTG)
GuidanceGuidance for preparing and submitting an application for inclusion of a Class 1 biological on the ARTG. -
-
GuidanceGuidance on how to access and use the Permissible Ingredients Determination for the purposes of submitting applications for substances in listed and assessed listed medicines.
-
GuidanceGuidance about the administrative information to support assessed listed medicine applications.
-
GuidanceGuidance on our approved terminology for medicines.
-
GuidanceRisk management plans for medicines and biologicals has been updated with new content, new Australia-Specific Annex and a new form.
-
GuidanceGuidance about information required for an assessed listed medicine application to pass preliminary assessment and proceed to evaluation.
-
GuidanceGuidance on the two mechanisms to provide information about a drug substance sourced from a third-party manufacturer.